VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 19, 2013) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC) is pleased to announce that through calendar year 2013 the Company has been applying its enabling Foundation Trinity™ Technology to proteins targeted for the treatment of cancers. Advanced, targeted therapies are intended to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics market in the near future. APC's technology will enable not only therapy targeted for tumor cells, but also the delivery of combination therapy in a single, pure therapeutic agent. To achieve this, it has been the Company's intention to utilize a unique protein, not only as a delivery system to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface - both key to efficient manufacturing and product development. What is more, the protein itself appears to possess immunotherapeutic properties. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry. This vision, the unique nature of the protein, and the ability to apply its proprietary enabling chemical technology to modification of the protein, differentiate APC from the competition.
Since the Company has made the targeted delivery of anti-cancer drugs to tumor cells its point of focus, APC has prepared several molecules using its patent-pending technology, which the Company regards as the first of a number of series that the Company has conceived as potential anti-cancer agents. To test these molecules against tumor cells and animal models of cancer to meet preclinical requirements, the Company has executed agreements with academic collaborators who are experts in the field of cancer. In the first round of testing, all members of the first series exhibited high affinity for specific cancer cells and no obvious toxic effects on healthy cells. The unmodified protein alone has demonstrated the ability to retard tumor growth. A protein conjugate prepared by APC and its collaborators has been shown to concentrate in tumors.
Company scientists are excited by these results, and the Company plans to select a lead member of each series for advanced preclinical development. It expects that this testing will occur over the next few months to measure the relevant parameters in preclinical models leading to the selection of candidates with the best mix of properties for further development. The Company plans, concurrently, to seek out Corporate Partners in the pharmaceutical industry for joint efforts or licensing deals, which would support Company programs and advance eligible candidates toward clinical trials.
Alexander Krantz, President and CEO, stated, "The Company is grateful for the support and encouragement it has received from its investors and delighted with the direction and progress it has made this past year. We will be working diligently toward our objectives to treat this dreaded disease with kinder and gentler drugs, and look forward to 2014 as a pivotal year for the Company. Our very best wishes to all for the Holidays and New Year."
APC specializes in the development and patenting of advanced methods and platform technologies designed to deliver drugs to specific cellular targets. The Company's patent-pending technology creates transportation systems for drugs to target cells that need to be destroyed, such as cancer cells. APC uses its proprietary enabling technology for chemical modification of the carrier proteins. These methods allow the drug, in accord with regulatory requirements, to be site-specifically attached to the carrier protein which tracks to cancers cells. APC is focused on developing the first commercial application of cancer cell targeting by a specific protein family that has an affinity for cancer cells. Due to its high affinity for a target receptor on cancer cells, the protein can function as a transport system for drugs linked to its surface, with the prospect of avoiding the debilitating toxic effects that have plagued the use of chemotherapeutic drugs.
By virtue of similar affinity of the protein family for cells in the process of dying, the foregoing technologies are also applicable to the repair of cells where loss of function is a critical event, such as in eye diseases and myocardial infarction.
ON BEHALF OF THE BOARD
Alexander (Allen) Krantz, President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.